Yesterday 28 October, MPE provided feedback, as part of a public consultation open to all categories of stakeholders, on the Implementing Regulation on joint scientific consultations on medicinal products for human use at Union level. This is the fourth implementing act (out of six planned to be adopted this year) paving the road for the…
The Myeloma Patients Europe (MPE) European Young Myeloma Patient Group (EYMPG) held the webinar “Importance of good nutrition and healthy diet for young myeloma patients”. The webinar was given by Inês Almada Correia, Nutritionist specialising in Oncology and Autoimmunity, from Portugal. Watch the recording below: Learn more about the EYMPG here.
September is an important month for Myeloma Patients Europe (MPE) and our members. Each year, as part of Blood Cancer Awareness Month, we hold European Myeloma Day on 27 September. This year focused on highlighting the role of clinical trials in advancing myeloma treatments and improving patients’ quality of life. Throughout September, our members organised different activities to raise awareness of myeloma…
Brussels, 27 September 2024 – Today is European Myeloma Day, a date dedicated to raising awareness of key issues affecting myeloma patients across Europe. This year, Myeloma Patients Europe (MPE) is highlighting the role of clinical trials in advancing myeloma treatments and improving patients Quality of Life (QoL). Despite of the importance of clinical trials…
On 19 September the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a new indication for daratumumab (Darzalex®, commercialised by Janssen). The new indication is a combination of daratumumab, bortezomib, lenalidomide and dexamethasone and it brings a significant benefit with respect to progression-free survival compared to…
Every myeloma patient has a story to tell. And every story captures a very personal experience of our incurable blood cancer. Living with myeloma is more than navigating the physical challenges of illness and treatment. It is also about finding a path through mental health issues: toxic thoughts, rollercoaster emotions and imperilled well-being. Because myeloma…
After the approval of the first bispecific antibody for myeloma last month, the National Institute for Health and Care Excellence (NICE, the United Kingdom’s public body for medicine appraisals) approved today, 16 July 2024, a second bispecific drug, teclistamab. Commercially known as Tecvayli® and marketed by Janssen, the drug has been approved for people at…
On the 21st of June NICE, the United Kingdom’s public body for medicine appraisals, approved the use of the UK’s first bispecific drug for myeloma, elranatamab. Evidence from an ongoing clinical trial showed that the drug can increase the length of time people are in remission. Based on this evidence, elranatamab, commercially known as…
